Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.

ABSTRACT: Over the past 20 years, several innovative therapies have been implemented in the treatment of lung cancer that have had reported survival benefits in clinical trials. Whether these improvements translate into the clinic setting has not been studied yet. We retrospectively analyzed all patients consecutively treated at Institute Curie for metastatic lung cancer. Diagnosis date was used to define three periods, based on the approvals of novel treatment strategies in the first-line setting, including targeted therapies in 2010 and immunotherapy in 2018. Endpoints included Overall survival (OS), survival rate of 2 years and 5 years, and a conditional survival rate of 2 years (if still alive at 6 months from treatment initiation). A total of 673 patients were identified for Period 1-2000 to 20

SUBMITTER: Basse C 

PROVIDER: S-EPMC11312246 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature